Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Not yet recruiting × erdafitinib × Clear all

Phase

Status

Active not recruiting 7 Terminated 3 Completed 2 Withdrawn 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Cisplatin 67 Carboplatin 66 Bevacizumab 55 Oxaliplatin 50 Radiotherapy 47 Drug Therapy 47 Capecitabine 47 tislelizumab 44 Paclitaxel 44 toripalimab 42 pembrolizumab 42 Gemcitabine 42 sintilimab 32 Cyclophosphamide 31 Specimen Handling 29 130-nm albumin-bound paclitaxel 28 anlotinib 25 Surgical Procedures, Operative 24 Pemetrexed 23 Docetaxel 23 Injections 22 lenvatinib 21 Fluorouracil 21 apatinib 20 Etoposide 19 Biopsy 19 camrelizumab 17 Radiosurgery 17 Magnetic Resonance Spectroscopy 17 Immune Checkpoint Inhibitors 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡